[(1S,2R)-2-氨基环己基]甲醇 | 213993-30-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: [(1S,2R)-2-氨基环己基]甲醇
• 英文名称: ((1S,2R)-2-aminocyclohexyl)methanol
• 英文别名: [(1S,2R)-2-aminocyclohexyl]methanol
• CAS: 213993-30-7
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: GCWPGEWXYDEQAY-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [(1S,2R)-2-氨基环己基]甲醇 以 四氢呋喃 、 甲苯 为溶剂， 反应 5.0h， 生成 (1S,2R)-2-[(3-phenylthioureido)cyclohex-3-yl]methyl imidazole-1-carboxylate
  参考文献：
  名称：

  Stereoselective Synthesis and Cytoselective Toxicity of Monoterpene-Fused 2-Imino-1,3-thiazines

  摘要：

  以基于单萜的β-氨基酸获得的蒎烷、阿蒎烷和卡烷为基础的1,3-氨基醇为原料，以单萜稠合的2-亚氨基-1,3-噻嗪为主要产品，并以2-硫代-通过两步或三步合成制备副产物 1,3-恶嗪。当由1,3-氨基醇和异硫氰酸芳基酯制备的硫脲加合物与CDI在温和条件下反应时，分离出O-咪唑基羰基中间体，该中间体可以在微波条件下转化为所需的1,3-噻嗪类化合物。 1,3-噻嗪和2-硫代-1,3-恶嗪副产物也可以通过CDI和微波辐射的一步反应制备。闭环过程扩展到基于环烷烃的γ-羟基硫脲。基于carane和apopinane的衍生物对一组人类贴壁癌细胞系（HeLa、A2780、MCF7和A431）表现出显着的抗增殖活性。

  DOI：

  10.3390/molecules191015918
• 作为产物：
  描述：

  (1S,2R)-2-氨基-环己烷羧酸乙酯 在 lithium aluminium tetrahydride 作用下， 生成 [(1S,2R)-2-氨基环己基]甲醇
  参考文献：
  名称：

  Stereoselective Synthesis and Cytoselective Toxicity of Monoterpene-Fused 2-Imino-1,3-thiazines

  摘要：

  以基于单萜的β-氨基酸获得的蒎烷、阿蒎烷和卡烷为基础的1,3-氨基醇为原料，以单萜稠合的2-亚氨基-1,3-噻嗪为主要产品，并以2-硫代-通过两步或三步合成制备副产物 1,3-恶嗪。当由1,3-氨基醇和异硫氰酸芳基酯制备的硫脲加合物与CDI在温和条件下反应时，分离出O-咪唑基羰基中间体，该中间体可以在微波条件下转化为所需的1,3-噻嗪类化合物。 1,3-噻嗪和2-硫代-1,3-恶嗪副产物也可以通过CDI和微波辐射的一步反应制备。闭环过程扩展到基于环烷烃的γ-羟基硫脲。基于carane和apopinane的衍生物对一组人类贴壁癌细胞系（HeLa、A2780、MCF7和A431）表现出显着的抗增殖活性。

  DOI：

  10.3390/molecules191015918

文献信息

• [EN] BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BENZODIOXANES DE PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012125598A1

  公开（公告）日：2012-09-20

  The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式(I)的化合物：其中R1至R3、A、X和n如本文所定义。式(I)的化合物可用作白三烯A4水解酶(LTA4H)的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式(I)化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• Pharmaceutically active pyrrolidine derivatives as bax inhibitors
  申请人：——

  公开号：US20030171309A1

  公开（公告）日：2003-09-11

  The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR<6>R<7>, NOR<6>, NNR<6>R<7>; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NR<8>R<9> or represents a heterocyclic residue having the formula (II) wherein Q is NR<10>, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及新的取代吡咯烷衍生物的化学式(I)。所述化合物通常用作药用活性化合物。具体来说，化学式(I)的吡咯烷衍生物在治疗和/或预防神经退行性疾病、与多谷氨酸氨基酸序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病方面具有用处。所述吡咯烷衍生物显示出对细胞死亡促进子Bax和/或导致Bax激活途径的调节作用，最显著地是下调至抑制活性，并因此允许阻止细胞色素(c)的释放。本发明还涉及新的具有药用活性的取代吡咯烷衍生物，以及它们的制备方法，其中X选自O、S、CR<6>R<7>、NOR<6>、NNR<6>R<7>组成的群；A选自—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO2-、—SO2NH—；—CH2-；B是一个群—(C═O)—NR<8>R<9>或代表具有化学式(II)的杂环残基，其中Q是NR<10>、O或S；n是选自0、1或2的整数；Y、Z和E与它们连接的两个碳共同形成一个5-6成员芳香族或杂芳族环。
• Pharmaceutically active pyrrolidine derivatives
  申请人：——

  公开号：US20030212012A1

  公开（公告）日：2003-11-13

  The present invention is related to pyrrolidine derivatives of formula (I). Said 1 compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。
• Novel Compounds
  申请人：Cheng Yun-Xing

  公开号：US20070259888A1

  公开（公告）日：2007-11-08

  Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein X, R 1 , R 2 and R 3 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  公式I的化合物，或其药用盐：其中X、R1、R2和R3如规范中定义的那样，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• Structure-enantioselectivity effects in 3,4-dihydropyrimido[2,1-b]benzothiazole-based isothioureas as enantioselective acylation catalysts
  作者：Dorine Belmessieri、Caroline Joannesse、Philip A. Woods、Callum MacGregor、Caroline Jones、Craig D. Campbell、Craig P. Johnston、Nicolas Duguet、Carmen Concellón、Ryan A. Bragg、Andrew D. Smith

  DOI：10.1039/c0ob00515k

  日期：——

  The catalytic activity and enantioselectivity in the kinetic resolution of (±)-1-naphthylethanol with a range of structurally related 3,4-dihydropyrimido[2,1-b]benzothiazole-based catalysts is examined. Of the isothiourea catalysts screened, (2S,3R)-2-phenyl-3-isopropyl substitution proved optimal, giving good levels of selectivity in the kinetic resolution of a number of secondary alcohols (S values up to >100 at ∼50% conversion). Low catalyst loadings (0.10–0.25 mol%) of the optimal isothiourea can be used to generate enantiopure alcohols (>99% ee) in good yields.

  本文研究了一系列结构相关的3,4-二氢嘧咪啶[2,1-b]苯并噻唑基催化剂在对(±)-1-萘乙醇的动力学分辨过程中的催化活性和对映选择性。在筛选的异硫脲催化剂中，(2S,3R)-2-苯基-3-异丙基取代物表现出最佳效果，在多种二次醇的动力学分辨中实现了良好的选择性（S值在约50%转化率时可达到≥100）。最佳异硫脲催化剂的低负载量（0.10–0.25 mol%）可用于生成对映纯醇（对映体过量≥99%）且产率良好。